Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Activomin is a natural humic acid preparation, specifically containing the standardized WH67 humic acid extract derived from lignite (brown coal). Developed and manufactured by WH Pharmawerk Weinböhla GmbH, it is classified as a medical device in Germany rather than a conventional pharmaceutical drug. Activomin is primarily indicated for the treatment of gastrointestinal and metabolic disorders, including diarrhea-predominant irritable bowel syndrome (IBS-D), diarrheal diseases, and weakened immune defenses. Its mechanism of action involves the high-molecular-weight humic acids remaining largely unabsorbed in the gastrointestinal tract, where they act as an adsorbent to bind toxins, inflammatory mediators, and pathogens. Additionally, it is thought to modulate the colonic microbiome and support gut barrier function. The product is administered orally in capsule form and has been evaluated in randomized, double-blind, placebo-controlled clinical trials for symptom improvement in patients with IBS.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Activomin.